BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Local control and distant metastasis after electrochemotherapy of a canine anal melanoma.

Canine anal melanoma is an aggressive neoplasm that rapidly leads to constipation in dogs, thus mimicking the behavior of their human counterpart.

[MeSH-major] Anus Neoplasms / veterinary. Dog Diseases / drug therapy. Dog Diseases / pathology. Electrochemotherapy. Melanoma / veterinary

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18019432.001).

[ISSN] 0258-851X

[Journal-full-title] In vivo (Athens, Greece)

[ISO-abbreviation] In Vivo

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Greece

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Haemorrhoids or anal melanoma, importance of preoperative histopathological examination: a case report.

Haemorrhoids are the most common lesion affecting the anorectal region, whereas anal melanoma constitutes only 1% to 3% of all malignant tumours of anal canal.

We report a case of a female with classical clinical presentation of prolapsed haemorrhoids which on histopathological evaluation was found to be malignant melanoma.

The case highlights the significance of exact diagnosis prior to any surgical intervention.

[MeSH-major] Hemorrhoids. Melanoma

[MeSH-minor] Anus Neoplasms. Humans. Rectum. Skin Neoplasms

MedlinePlus Health Information. consumer health - Hemorrhoids.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20496274.001).

[ISSN] 1233-9687

[Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists

[ISO-abbreviation] Pol J Pathol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Poland

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anal melanoma.

Anal melanoma is rare and aggressive malignancy.

Unlike cutaneous melanoma, anal melanoma has no known risk factors.

There are no long-term survivors of stage II or III disease; therefore, early diagnosis and treatment remain crucial.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] N Engl J Med. 1999 Apr 29;340(17):1341-8 [10219070.001]

[Cites] Dis Colon Rectum. 1999 Sep;42(9):1203-8 [10496563.001]

[Cites] Ann Surg. 1999 Oct;230(4):453-63; discussion 463-5 [10522715.001]

[Cites] J Clin Oncol. 1999 Jul;17(7):2105-16 [10561265.001]

[Cites] Oncology (Williston Park). 1999 Nov;13(11):1561-74; discussion 1574 passim [10581603.001]

[Cites] Clin Cancer Res. 2000 Mar;6(3):863-7 [10741708.001]

[Cites] Recent Results Cancer Res. 2000;157:178-89 [10857171.001]

[Cites] Curr Oncol Rep. 2000 Jul;2(4):292-9 [11122856.001]

[Cites] Chir Ital. 2000 Jul-Aug;52(4):329-34 [11190522.001]

[Cites] South Med J. 2001 Sep;94(9):880-5 [11592745.001]

[Cites] Tech Coloproctol. 2001 Apr;5(1):51-4 [11793262.001]

[Cites] J Clin Oncol. 2002 Apr 1;20(7):1818-25 [11919239.001]

[Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):964-72 [11958890.001]

[Cites] Ann Surg. 2002 Oct;236(4):438-48; discussion 448-9 [12368672.001]

[Cites] J Clin Oncol. 2002 Dec 1;20(23):4555-8 [12454112.001]

[Cites] Melanoma Res. 2002 Aug;12(4):395-8 [12170190.001]

[Cites] Hepatogastroenterology. 2002 Nov-Dec;49(48):1545-8 [12397731.001]

[Cites] Histopathology. 2002 Dec;41(6):519-25 [12460204.001]

[Cites] Int J Gastrointest Cancer. 2002;32(1):53-6 [12630771.001]

[Cites] Br J Cancer. 2003 Dec 1;89(11):2019-22 [14647131.001]

[Cites] Cancer. 2004 Apr 1;100(7):1478-83 [15042682.001]

[Cites] Radiology. 2004 Jul;232(1):181-6 [15220501.001]

[Cites] Anticancer Drugs. 2005 Mar;16(3):345-8 [15711188.001]

[Cites] J Clin Pathol. 1963 Mar;16(2):126-32 [16811001.001]

[Cites] Int Surg. 1980 Sep-Oct;65(5):423-6 [7451062.001]

[Cites] J Natl Cancer Inst. 1995 Nov 15;87(22):1710-3 [7473820.001]

[Cites] J Surg Oncol. 1995 Feb;58(2):118-20 [7844981.001]

[Cites] Dis Colon Rectum. 1995 Feb;38(2):146-51 [7851168.001]

[Cites] Ann N Y Acad Sci. 1993 Aug 12;690:167-77 [8368735.001]

[Cites] Int J Colorectal Dis. 1993 Jul;8(2):81-6 [8409692.001]

[Cites] Gastroenterology. 1993 Jan;104(1):174-8 [8419240.001]

[Cites] Histopathology. 1993 Mar;22(3):261-4 [8495957.001]

[Cites] Cancer. 2000 Jan 1;88(1):88-94 [10618610.001]

[Cites] Ann Surg Oncol. 2000 Mar;7(2):87-97 [10761786.001]

[Cites] Ann Surg Oncol. 2000 Oct;7(9):680-4 [11034246.001]

[Cites] Surg Today. 2001;31(6):527-9 [11428607.001]

[Cites] Surg Oncol. 2001 Jul-Aug;10(1-2):53-9 [11719029.001]

[Cites] Br J Surg. 2002 Apr;89(4):389-96 [11952577.001]

[Cites] J Am Coll Surg. 2003 Feb;196(2):206-11 [12595048.001]

[Cites] Can J Surg. 2003 Oct;46(5):345-9 [14577706.001]

[Cites] Melanoma Res. 2004 Apr;14(2):147-50 [15057046.001]

[Cites] Br J Surg. 2004 Sep;91(9):1183-7 [15449271.001]

[Cites] Am J Surg. 2005 Apr;189(4):446-9 [15820458.001]

[Cites] Dis Colon Rectum. 1990 Oct;33(10):874-7 [1698595.001]

[Cites] J Clin Oncol. 1991 May;9(5):729-35 [2016615.001]

[Cites] Surgery. 1990 Jan;107(1):1-9 [2296748.001]

[Cites] Arch Surg. 1990 Mar;125(3):313-6 [2306178.001]

[Cites] Radiother Oncol. 1989 Nov;16(3):169-82 [2587808.001]

[Cites] Cancer. 1988 Apr 1;61(7):1364-70 [3345491.001]

[Cites] Br J Surg. 1986 Jan;73(1):68-9 [3947881.001]

[Cites] Acta Chir Scand. 1974;140(1):68-72 [4819025.001]

[Cites] CA Cancer J Clin. 1966 May-Jun;16(3):111-4 [4957071.001]

[Cites] Dis Colon Rectum. 1967 May-Jun;10(3):161-76 [6026797.001]

[Cites] Cancer. 1981 Apr 1;47(7):1891-900 [6164474.001]

[Cites] Cancer. 1984 Mar 15;53(6):1299-305 [6362841.001]

[Cites] Am J Surg. 1983 Sep;146(3):336-8 [6614323.001]

[Cites] N Engl J Med. 1982 Oct 7;307(15):913-6 [7050717.001]

[Cites] Surg Gynecol Obstet. 1982 Mar;154(3):337-41 [7064068.001]

[Cites] Dis Colon Rectum. 1982 Oct;25(7):693-703 [7128372.001]

[Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):772-7 [7172945.001]

[Cites] Br J Surg. 1981 Sep;68(9):667-8 [7272698.001]

[Cites] Dis Colon Rectum. 1980 Mar;23(2):122-4 [7379659.001]

[Cites] Arch Surg. 1996 Sep;131(9):975-9; 979-80 [8790168.001]

[Cites] Ann Surg. 1996 Sep;224(3):255-63; discussion 263-6 [8813254.001]

[Cites] Ann Oncol. 1996 Oct;7(8):827-35 [8922197.001]

[Cites] Eur J Surg Oncol. 1996 Dec;22(6):598-601 [9005147.001]

[Cites] Surg Oncol. 1996 Aug;5(4):165-8 [9067564.001]

[Cites] J Exp Clin Cancer Res. 1997 Mar;16(1):81-5 [9148866.001]

[Cites] Dis Colon Rectum. 1997 Jun;40(6):661-8 [9194459.001]

[Cites] Surg Today. 1997;27(8):753-6 [9306593.001]

[Cites] J Am Coll Surg. 1998 Jul;187(1):69-77; discussion 77-9 [9660028.001]

[Cites] Eur J Surg Oncol. 1998 Aug;24(4):303-7 [9724998.001]

[Cites] J Clin Oncol. 1998 Sep;16(9):2921-9 [9738559.001]

[Cites] Cancer. 1998 Oct 15;83(8):1664-78 [9781962.001]

[Cites] Acta Oncol. 1998;37(5):497-9 [9831382.001]

[Cites] Eur J Cancer. 1998 Jul;34 Suppl 3:S22-6 [9849405.001]

[Cites] J Natl Cancer Inst. 1998 Dec 16;90(24):1894-900 [9862627.001]

[Cites] Gynecol Oncol. 1998 Dec;71(3):476-80 [9887254.001]

[Cites] J Clin Oncol. 1999 Mar;17(3):976-83 [10071292.001]

(PMID = 20011314.001).

[ISSN] 1530-9681

[Journal-full-title] Clinics in colon and rectal surgery

[ISO-abbreviation] Clin Colon Rectal Surg

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC2780102

[Keywords] NOTNLM ; Melanoma / abdominoperineal resection / anal / malignancy / wide local excision

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Overexpression of Akt converts radial growth melanoma to vertical growth melanoma.

Melanoma is the cancer with the highest increase in incidence, and transformation of radial growth to vertical growth (i.e., noninvasive to invasive) melanoma is required for invasive disease and metastasis.

We have previously shown that p42/p44 MAP kinase is activated in radial growth melanoma, suggesting that further signaling events are required for vertical growth melanoma.

Akt, a signaling molecule downstream of PI3K, was introduced into the radial growth WM35 melanoma in order to test whether Akt overexpression is sufficient to accomplish this transformation.

We demonstrated that Akt was associated with malignant transformation of melanoma through at least 2 mechanisms.

Targeting Akt and ROS may be of therapeutic importance in treatment of advanced melanoma.

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Mol Carcinog. 2002 Apr;33(4):206-18 [11933074.001]

[Cites] Mol Med. 2002 Jan;8(1):1-8 [11984000.001]

[Cites] Am J Physiol Cell Physiol. 2002 Jun;282(6):C1212-24 [11997235.001]

[Cites] Methods Mol Biol. 2002;189:67-73 [12094595.001]

[Cites] Science. 1997 Mar 14;275(5306):1649-52 [9054359.001]

[Cites] J Bioenerg Biomembr. 1997 Aug;29(4):365-77 [9387097.001]

[Cites] Oncogene. 1998 Jan 29;16(4):523-31 [9484842.001]

[Cites] Am J Pathol. 1998 Nov;153(5):1435-42 [9811334.001]

[Cites] Science. 1998 Nov 13;282(5392):1318-21 [9812896.001]

[Cites] EMBO J. 1999 Apr 1;18(7):1824-31 [10202146.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4820-5 [10220377.001]

[Cites] Clin Cancer Res. 1999 May;5(5):1197-202 [10353757.001]

[Cites] Nature. 1999 Sep 2;401(6748):79-82 [10485709.001]

[Cites] Cancer Cell. 2002 Jul;2(1):5-7 [12150818.001]

[Cites] J Neurosci. 2002 Aug 15;22(16):7006-15 [12177198.001]

[Cites] J Clin Invest. 2002 Sep;110(5):643-50 [12208865.001]

[Cites] Nat Med. 2002 Oct;8(10):1153-60 [12244302.001]

[Cites] Cancer Res. 2002 Nov 15;62(22):6674-81 [12438266.001]

[Cites] Clin Cancer Res. 2002 Dec;8(12):3728-33 [12473582.001]

[Cites] Cancer Res. 2002 Dec 15;62(24):7335-42 [12499277.001]

[Cites] J Biol Chem. 2003 Mar 14;278(11):9790-5 [12514183.001]

[Cites] J Biol Chem. 2003 Apr 4;278(14):12361-6 [12517744.001]

[Cites] Mol Cell Biol. 2003 Oct;23(20):7315-28 [14517300.001]

[Cites] Mol Cell Biol. 2004 Jan;24(2):730-40 [14701745.001]

[Cites] Biochem Biophys Res Commun. 2004 Jan 23;313(4):984-91 [14706639.001]

[Cites] J Inherit Metab Dis. 2003;26(7):647-58 [14707513.001]

[Cites] J Neurochem. 2003 Dec;87(6):1427-35 [14713298.001]

[Cites] Pigment Cell Res. 2004 Feb;17(1):74-83 [14717848.001]

[Cites] J Invest Dermatol. 2004 Feb;122(2):337-41 [15009714.001]

[Cites] Cell. 2004 Apr 16;117(2):225-37 [15084260.001]

[Cites] Cancer Res. 2004 Jun 1;64(11):3892-9 [15172999.001]

[Cites] Carcinogenesis. 2004 Jul;25(7):1157-63 [14963017.001]

[Cites] Curr Biol. 2004 Jul 27;14(14):1296-302 [15268862.001]

[Cites] Cancer Cell. 2004 Aug;6(2):117-27 [15324695.001]

[Cites] Cancer Res. 2004 Oct 1;64(19):7002-10 [15466193.001]

[Cites] Nature. 2004 Oct 21;431(7011):997-1002 [15496926.001]

[Cites] Z Naturforsch B. 1970 Mar;25(3):332-3 [4392802.001]

[Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]

[Cites] Anal Biochem. 1971 Nov;44(1):276-87 [4943714.001]

[Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]

[Cites] Pediatr Res. 1982 Aug;16(8):632-7 [6287402.001]

[Cites] Free Radic Res Commun. 1988;5(2):67-75 [2463958.001]

[Cites] Cancer Res. 1991 Feb 1;51(3):794-8 [1846317.001]

[Cites] Biochemistry. 1992 Sep 8;31(35):8300-6 [1525167.001]

[Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]

[Cites] Mol Cell. 2004 Dec 3;16(5):819-30 [15574336.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):719-24 [15647368.001]

[Cites] Clin Chem. 2005 Feb;51(2):305-11 [15590750.001]

[Cites] J Clin Oncol. 2005 Mar 1;23(7):1473-82 [15735123.001]

[Cites] FEBS Lett. 2000 Jun 30;476(1-2):52-4 [10878249.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8010-4 [10869423.001]

[Cites] J Mol Biol. 2000 Sep 8;302(1):205-17 [10964570.001]

[Cites] Trends Biochem Sci. 2000 Oct;25(10):459-61 [11050424.001]

[Cites] Nat Neurosci. 2000 Dec;3(12):1301-6 [11100151.001]

[Cites] Nature. 2001 Jan 11;409(6817):207-11 [11196646.001]

[Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5550-5 [11331784.001]

[Cites] Hum Genet. 2001 Jul;109(1):33-9 [11479733.001]

[Cites] Antioxid Redox Signal. 2001 Aug;3(4):697-709 [11554455.001]

[Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]

[Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):715-20 [11805326.001]

[Cites] Nat Rev Cancer. 2001 Nov;1(2):142-50 [11905805.001]

[Cites] Nat Genet. 2005 Jul;37(7):745-9 [15951821.001]

[Cites] Cancer Res. 2005 Jul 15;65(14):6282-93 [16024630.001]

[Cites] Cancer. 2005 Sep 1;104(5):1045-8 [16007689.001]

[Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]

[Cites] Cancer Cell. 2005 Dec;8(6):443-54 [16338658.001]

[Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D247-51 [16381856.001]

[Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2301s-2307s [16609049.001]

[Cites] Cancer Res. 2006 Apr 15;66(8):4182-90 [16618740.001]

[Cites] Science. 2006 Jul 28;313(5786):521-2 [16809487.001]

[Cites] Melanoma Res. 2006 Dec;16(6):471-8 [17119447.001]

[Cites] Blood. 2007 Jan 15;109(2):560-5 [16990598.001]

(PMID = 17318262.001).

[ISSN] 0021-9738

[Journal-full-title] The Journal of clinical investigation

[ISO-abbreviation] J. Clin. Invest.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA27502; United States / NIAMS NIH HHS / AR / R01 AR02030; United States / NCI NIH HHS / CA / CA59327; United States / NCI NIH HHS / CA / P01 CA059327; United States / NCI NIH HHS / CA / P01 CA027502

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / DNA, Mitochondrial; 0 / Reactive Oxygen Species; 0 / Vascular Endothelial Growth Factor A; EC 1.6.- / Nox4 protein, rat; EC 1.6.3.1 / NADPH Oxidase; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt

[Other-IDs] NLM/ PMC1797605

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Multiple bilateral choroidal metastasis from anal melanoma.

A 58-year-old Caucasian woman with bleeding per rectum had a melanoma of the anal canal.

[MeSH-major] Anus Neoplasms / diagnosis. Choroid Neoplasms / secondary. Melanoma / diagnosis. Melanoma / secondary

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17701012.001).

[ISSN] 1341-9625

[Journal-full-title] International journal of clinical oncology

[ISO-abbreviation] Int. J. Clin. Oncol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Effect of xanthohumol on melanogenesis in B16 melanoma cells.

Xanthohumol (XH), the principal prenylflavonoid of the hop plant (Humulus lupulus L.), dose-dependently inhibited isobutylmethylxanthine (IBMX)-induced melanogenesis in B16 melanoma cells, with little cytotoxicity at the effective concentrations.

[MeSH-minor] 1-Methyl-3-isobutylxanthine / pharmacology. Animals. Cell Line. Cell Survival / drug effects. Colforsin / pharmacology. Dose-Response Relationship, Drug. Down-Regulation. Drug Antagonism. Flavonoids. Intramolecular Oxidoreductases / antagonists & inhibitors. Intramolecular Oxidoreductases / biosynthesis. Melanoma, Experimental. Membrane Glycoproteins / antagonists & inhibitors. Membrane Glycoproteins / biosynthesis. Mice. Microphthalmia-Associated Transcription Factor / antagonists & inhibitors. Microphthalmia-Associated Transcription Factor / biosynthesis. Monophenol Monooxygenase / antagonists & inhibitors. Monophenol Monooxygenase / biosynthesis. Monophenol Monooxygenase / genetics. Oxidoreductases / antagonists & inhibitors. Oxidoreductases / biosynthesis. Signal Transduction / drug effects. alpha-MSH / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Investig Dermatol Symp Proc. 1999 Sep;4(1):24-8 [10537003.001]

[Cites] Mol Pharmacol. 1970 Nov;6(6):597-603 [4322367.001]

[Cites] Pigment Cell Res. 2000 Apr;13(2):60-9 [10841026.001]

[Cites] Pigment Cell Res. 2000 Aug;13(4):230-40 [10952390.001]

[Cites] Pigment Cell Res. 2000 Aug;13(4):248-52 [10952392.001]

[Cites] J Agric Food Chem. 2000 Sep;48(9):3876-84 [10995285.001]

[Cites] Pigment Cell Res. 2000;13 Suppl 8:94-7 [11041364.001]

[Cites] Exp Mol Med. 2001 Sep 30;33(3):131-5 [11642548.001]

[Cites] Mol Cancer Ther. 2002 Sep;1(11):959-69 [12481418.001]

[Cites] Biochem Biophys Res Commun. 2003 Feb 7;301(2):610-6 [12565907.001]

[Cites] Phytochemistry. 2004 May;65(10):1317-30 [15231405.001]

[Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]

[Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]

[Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]

[Cites] FEBS Lett. 1985 Apr 22;183(2):430-2 [2985438.001]

[Cites] Biosci Biotechnol Biochem. 1997 Jan;61(1):158-9 [9028043.001]

[Cites] Pigment Cell Res. 1997 Oct;10(5):288-97 [9359624.001]

[Cites] Antiviral Res. 2004 Dec;64(3):189-94 [15550272.001]

[Cites] In Vivo. 2005 Jan-Feb;19(1):103-7 [15796161.001]

[Cites] J Antimicrob Chemother. 2005 Jun;55(6):883-7 [15824094.001]

[Cites] Mol Nutr Food Res. 2005 Sep;49(9):837-43 [15995977.001]

[Cites] Mol Nutr Food Res. 2005 Sep;49(9):861-7 [16092070.001]

[Cites] Pigment Cell Res. 2006 Apr;19(2):146-53 [16524430.001]

[Cites] Trends Mol Med. 2006 Sep;12(9):406-14 [16899407.001]

[Cites] Acta Pharmacol Sin. 2006 Nov;27(11):1467-73 [17049123.001]

[Cites] Phytother Res. 2006 Nov;20(11):921-34 [16841367.001]

[Cites] Pigment Cell Res. 2006 Dec;19(6):550-71 [17083484.001]

[Cites] Nature. 2007 Feb 22;445(7130):843-50 [17314970.001]

[Cites] FASEB J. 2007 Apr;21(4):976-94 [17242160.001]

[Cites] Mutat Res. 2007 Aug 15;632(1-2):1-8 [17590382.001]

[Cites] Dermatol Clin. 2007 Jul;25(3):283-91, vii [17662894.001]

[Cites] J Biol Chem. 2007 Sep 21;282(38):27557-61 [17635904.001]

[Cites] Apoptosis. 2007 Nov;12(11):1953-63 [17874298.001]

[Cites] Int J Mol Med. 2007 Nov;20(5):763-7 [17912471.001]

[Cites] Methods Enzymol. 1987;142:165-9 [3037257.001]

[Cites] Int J Biochem. 1987;19(12):1141-7 [3125075.001]

[Cites] J Biol Chem. 1993 Jun 5;268(16):11742-9 [7685020.001]

[Cites] J Biol Chem. 1994 Oct 28;269(43):27080-7 [7929451.001]

[Cites] EMBO J. 1994 Dec 15;13(24):5818-25 [7813420.001]

[Cites] Recent Prog Horm Res. 1996;51:287-317; discussion 318 [8701084.001]

[Cites] Exp Cell Res. 2000 Mar 15;255(2):135-43 [10694430.001]

(PMID = 18587269.001).

[ISSN] 1226-3613

[Journal-full-title] Experimental & molecular medicine

[ISO-abbreviation] Exp. Mol. Med.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Korea (South)

[Chemical-registry-number] 0 / Flavonoids; 0 / Melanins; 0 / Membrane Glycoproteins; 0 / Microphthalmia-Associated Transcription Factor; 0 / Mitf protein, mouse; 0 / Propiophenones; 1F7A44V6OU / Colforsin; 581-05-5 / alpha-MSH; EC 1.- / Oxidoreductases; EC 1.14.18.- / Tyrp1 protein, mouse; EC 1.14.18.1 / Monophenol Monooxygenase; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.3.12 / dopachrome isomerase; T4467YT1NT / xanthohumol; TBT296U68M / 1-Methyl-3-isobutylxanthine

[Other-IDs] NLM/ PMC2679287

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Sentinel lymph node biopsy for the staging of anal melanoma: report of two cases.

Primary melanoma of the anal region is a rare pathological entity and its prognosis is generally poor.

The aim of this report is to demonstrate the feasibility of the sentinel lymph node (SLN) procedure with combined technique in patients with anal melanoma.

We report of two cases with anal melanoma that had wide local excision of the primary lesion and was referred for further evaluation.

Consequently, we suggest that SLN procedure with combined technique is also a useful technique in malignant melanomas similar to other anal canal cancers.

[MeSH-major] Anus Neoplasms / diagnosis. Lymph Nodes / pathology. Melanoma / diagnosis. Neoplasm Staging / methods. Sentinel Lymph Node Biopsy / methods

[MeSH-minor] Adult. Female. Humans. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Radionuclide Imaging / methods. Technetium Tc 99m Sulfur Colloid / pharmacology

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17294674.001).

[ISSN] 0914-7187

[Journal-full-title] Annals of nuclear medicine

[ISO-abbreviation] Ann Nucl Med

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Malignancies of the anal margin and perianal skin.

Malignancies of the anal margin and perianal skin are relatively uncommon lesions, comprising 3 to 4% of all anorectal malignancies.

Commonly included in this group of cancers are Bowen's disease (intraepithelial squamous cell cancer), perianal Paget's disease (intraepithelial adenocarcinoma), invasive squamous cell cancer, basal cell cancer, and malignant melanoma.

Proper diagnosis requires a high index of suspicion on the part of the surgeon.

Innocent local irritations will resolve in a short time with appropriate therapy; those that persist must be biopsied for tissue diagnosis.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Dis Colon Rectum. 2008 Dec;51(12):1842-5 [18584248.001]

[Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]

[Cites] Dermatol Surg. 2007 Apr;33(4):427-31; discussion 431-2 [17430376.001]

[Cites] Br J Dermatol. 2007 Jan;156(1):11-21 [17199561.001]

[Cites] Dermatol Surg. 2001 Jun;27(6):587-90 [11442599.001]

[Cites] Dis Colon Rectum. 1997 Oct;40(10):1187-94 [9336114.001]

[Cites] Br J Dermatol. 1995 Jun;132(6):970-2 [7662577.001]

[Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]

[Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]

(PMID = 20436838.001).

[ISSN] 1530-9681

[Journal-full-title] Clinics in colon and rectal surgery

[ISO-abbreviation] Clin Colon Rectal Surg

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC2780245

[Keywords] NOTNLM ; Anal margin cancer / diagnosis / local excision / radiation therapy / treatment options

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Factors affecting survival in patients with anal melanoma.

Anal melanoma is an aggressive tumor with a predilection for early infiltration and distant spread, resulting in poor overall survival.

Because anal melanoma is rare, only small case series are reported in the literature, making it difficult to draw conclusions about optimal treatment and outcome.

The Surveillance, Epidemiology, and End Results database was used to identify patients with anal melanomas from 1973 to 2001.

In addition to demographics, disease extent at presentation, treatment administered, overall survival, and survival by decade of diagnosis were collected.

A total of 126 patients with a mean age of 69.2 years was diagnosed with anal melanoma.

Neither age at diagnosis, operation performed, nor use of radiation significantly affected survival.

Anal melanoma remains an uncommon but lethal disease.

[MeSH-major] Anus Neoplasms / mortality. Melanoma / mortality

MedlinePlus Health Information. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Melanoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17058735.001).

[ISSN] 0003-1348

[Journal-full-title] The American surgeon

[ISO-abbreviation] Am Surg

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Long-term outcomes after local excision and radical surgery for anal melanoma: data from a population database.

PURPOSE: Anal melanoma is rare and associated with a poor outcome.

This study evaluates survival of patients undergoing surgery for anal melanoma from a prospective, population-based database.

METHODS: Characteristics and survival of patients undergoing rectal resection or local excision for anal melanoma of the anus, anal canal, and overlapping region of the rectum from 1982 to 2002 were obtained from the Surveillance, Epidemiology and End Results database and compared.

CONCLUSION: Survival of patients with anal melanoma is similar after local excision or rectal resection irrespective of whether patients have localized or regional stage of disease.

[MeSH-major] Anus Neoplasms / surgery. Melanoma / surgery

MedlinePlus Health Information. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Melanoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20305438.001).

[ISSN] 1530-0358

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anal melanoma in the era of sentinel lymph node mapping: a diagnostic and therapeutic challenge.

Melanoma of the anal canal is a rare malignancy that often has an atypical presentation.

We explored the possibility of applying the technique of sentinel lymph node (SLN) mapping to anal melanoma.

SLN mapping was performed in 2 patients with anal melanoma.

One patient had a wide local excision of the anal lesion with house flap anoplasty, while the other had abdominoperineal resection with total mesorectal excision.

The technique of SLN mapping and biopsy is easily adapted to surgery for malignant melanoma of the anus.

[MeSH-major] Anus Neoplasms / diagnosis. Melanoma / diagnosis. Sentinel Lymph Node Biopsy / methods

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15868503.001).

[ISSN] 1123-6337

[Journal-full-title] Techniques in coloproctology

[ISO-abbreviation] Tech Coloproctol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Italy

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Melanoma with cartilaginous differentiation: Diagnostic challenge on fine-needle aspiration with emphasis on differential diagnosis.

Fine-needle aspiration (FNA) is a minimally invasive, fast, and accurate diagnostic method for the evaluation of patients with locally recurrent or distant metastases of malignant melanoma.

In the vast majority of cases, the diagnosis is straightforward with the characteristic cytologic features well documented in the literature.

Divergent differentiation (chondroid, neural, myofibroblastic, and osteocartilagenous) in a melanoma is rare and can potentially create diagnostic challenges if the evaluator is unaware of the same.

We report a case of a 46-year-old female with a history of primary anal melanoma who presented with a groin mass.

The FNA of the groin mass showed a neoplasm rich in chondroid matrix and raised the possibility of a second primary mesenchymal neoplasm rather than metastasis from the patient's known primary anal melanoma.

A review of the histologic features of the anal melanoma showed divergent chondroid differentiation in the anal melanoma with the metastatic deposit in the groin exhibiting extensive chondroid differentiation.

[MeSH-major] Anus Neoplasms / pathology. Cartilage / pathology. Inguinal Canal / pathology. Lymph Nodes / pathology. Melanoma / secondary

[MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / pathology. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis. Middle Aged

MedlinePlus Health Information. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Melanoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2008 Wiley-Liss, Inc.

(PMID = 18973120.001).

[ISSN] 1097-0339

[Journal-full-title] Diagnostic cytopathology

[ISO-abbreviation] Diagn. Cytopathol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Melanoma of the anal canal: a case series.

PURPOSE: Anal melanoma is an uncommon and aggressive cancer.

METHODS: The medical records of patients with anal melanoma treated at the H.

Lee Moffitt Cancer and Research Institute between 1987 and 2004 were reviewed.

Published anal melanoma studies, including more than ten patients with outcome data, also were reviewed.

RESULTS: Twelve patients were identified (8 percent of all cancer of the anal canal).

Four patients had nodal involvement, and one had bone metastases at the time of diagnosis.

Five of the 11 patients without metastatic disease relapsed or died within the first year of diagnosis (4 had local excision and 1 had abdominoperineal resection).

CONCLUSIONS: Anorectal melanoma is a rare and challenging disease.

[MeSH-major] Antineoplastic Agents / therapeutic use. Digestive System Surgical Procedures / methods. Melanoma. Rectal Neoplasms

[MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prevalence. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - Melanoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17468984.001).

[ISSN] 0012-3706

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Tumor types: colorectal, gastric, HCC, GE junction, small bowel, pancreas, bile duct, breast, bladder, ovarian, sarcoma, melanoma, anal, urethral, thymic, head & neck, unknown primary.

Clinical activity included 2 partial responses (small bowel cancer, 10.3 m; bladder cancer, 10 m) and 1 complete response (mucosal melanoma 10.3 m).

Of 25 pts with colorectal cancer, 11 had as best response SD for > 3m (median 6 m, range 4.2-15.4 m), despite failing ≥ 1 irinotecan-containing regimen.

Promising clinical activity is seen in mucosal melanoma and irinotecan-refractory colon cancer. (Supported by NCI R01CA67819) [Table: see text].

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963517.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Laparoscopic abdominoperineal resection for anorectal melanoma: a case report and review of the literature.

Anal melanoma is a rare colorectal disease, accounting for 4% of all anal malignancies.

Here we report the first case of a patient with anorectal melanoma who was treated laparoscopically.

The literature on anorectal melanoma has been reviewed and controversy still surrounds the optimal treatment modality.

[MeSH-major] Anal Canal / surgery. Anus Neoplasms / surgery. Melanoma / surgery. Rectal Neoplasms / surgery. Rectum / surgery. Skin Neoplasms / surgery

MedlinePlus Health Information. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Melanoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19692869.001).

[ISSN] 1534-4908

[Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques

[ISO-abbreviation] Surg Laparosc Endosc Percutan Tech

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Number-of-references] 16

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Melanoma of the anorectal region: the experience of the National Cancer Institute of Milano.

AIMS: This study describes the experience of the National Cancer Institute of Milano in the treatment of anorectal melanoma over the last 32 years.

However, even when a radical surgery was undergone, the prognosis of patients with anal melanoma remains dismal.

CONCLUSION: Prognosis of anal melanoma remains poor.

[MeSH-major] Anus Neoplasms / surgery. Melanoma / surgery. Rectal Neoplasms / surgery

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18602790.001).

[ISSN] 1532-2157

[Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

[ISO-abbreviation] Eur J Surg Oncol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Anal malignant melanoma. Case report and literature review].

[Transliterated title] Melanoma maligno anal. Reporte de casos y revisión de la literatura.

OBJECTIVE: To present two cases of anorectal malignant melanoma as due to its non specific presentation and rarity they are often misdiagnosed like hemorrhoids.

BACKGROUND: Anal melanomas are rare tumors that constitute less than 1% of the malignant colorectal tumors and represent both a diagnostic and therapeutic challenge to physicians.

Melanomas are often misdiagnosed by a lot of anorectal conditions and diagnosis must be suspected in patients with an anal mass.

CASE REPORT: We present two anorectal cases of malignant melanoma treated by wide local excision, the principal complain in both patients was the presence of an anal mass and bleeding.

CONCLUSIONS: Anal melanoma is a rare entity with a poor prognosis.

[MeSH-major] Anus Neoplasms / pathology. Melanoma / pathology

[MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19666318.001).

[ISSN] 0375-0906

[Journal-full-title] Revista de gastroenterología de México

[ISO-abbreviation] Rev Gastroenterol Mex

[Language] spa

[Publication-type] Case Reports; English Abstract; Journal Article; Review

[Publication-country] Mexico

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The indications for operation were primary rectal cancer (n = 31), recurrent rectal cancer (n = 6), intractable Crohn disease (n = 3), anal melanoma (n = 1), cloacogenic cancer (n = 1), squamous cell cancer (n = 1), and gastrointestinal stromal tumor (n = 1).

Despite the significant morbidity associated with this surgery, APR may provide beneficial treatment for select cases of low rectal cancer, end-stage inflammatory bowel disease, and anal malignancies.

MedlinePlus Health Information. consumer health - After Surgery.

MedlinePlus Health Information. consumer health - Crohn's Disease.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16468531.001).

[ISSN] 0003-1348

[Journal-full-title] The American surgeon

[ISO-abbreviation] Am Surg

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Malignant melanoma of the anorectum--a rare entity.

OBJECTIVE: Primary anorectal melanoma is a rare entity with a poor prognosis accounting for approximately 0.1-4.6% of anal tumours and 0.5-1.6% of all melanomas.

Almost 60% of patients have already disseminated disease at initial diagnosis.

METHOD: We report four cases of anorectal melanoma treated at our department from November 2006 to September 2008, as well as a review of the literature.

Three patients died on account of dissemination of melanoma, one patient is still alive.

CONCLUSION: Anal melanoma remains a deadly problem.

Clear guidelines for the therapy of anorectal melanoma have not been established.

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20066546.001).

[ISSN] 1435-2451

[Journal-full-title] Langenbeck's archives of surgery

[ISO-abbreviation] Langenbecks Arch Surg

[Language] ENG

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] Germany

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Melanoma adrenal metastasis: report of 3 cases and literature review].

OBJECTIVE: To investigate the clinical diagnosis, treatment and prognosis of melanoma adrenal metastasis.

METHODS: A total of 48 cases of malignant melanoma from 1985 to 2007 were reviewed.

And three cases of melanoma adrenal metastasis were analyzed.

Two cases had a history of cutaneous melanoma and another one suffered previously from anal melanoma.

The other two cases underwent complete resection of melanoma metastasis.

When contralateral adrenal metastasis of melanoma was found 6 months later, left adrenalectomy laparoscopically was performed.

CONCLUSION: Melanoma metastasis to adrenal gland is rare and it generally has a poor prognosis.

Patients with adrenal metastases from melanoma, either isolated or with a limited number of additional metastases, may achieve a survival benefit from surgical resection if all visible lesions are removed.

[MeSH-major] Adrenal Gland Neoplasms / secondary. Melanoma / pathology. Skin Neoplasms / pathology

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

MedlinePlus Health Information. consumer health - Melanoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20646432.001).

[ISSN] 0376-2491

[Journal-full-title] Zhonghua yi xue za zhi

[ISO-abbreviation] Zhonghua Yi Xue Za Zhi

[Language] chi

[Publication-type] Case Reports; English Abstract; Journal Article; Review

[Publication-country] China

[Number-of-references] 8

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Malignant melanoma of the anus and rectum].

There is approximately 300 cases of malignant melanoma written in the world literature.

We write up 13 operated from us for 15 years cases of melanoma of the anus and rectum.

[MeSH-major] Anal Canal / surgery. Anus Neoplasms / surgery. Melanoma / surgery. Rectal Neoplasms / surgery. Rectum / surgery

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21972686.001).

[ISSN] 0450-2167

[Journal-full-title] Khirurgii︠a︡

[ISO-abbreviation] Khirurgiia (Sofiia)

[Language] bul

[Publication-type] English Abstract; Journal Article

[Publication-country] Bulgaria

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Malignant melanoma of the anal region.

Malignant melanoma (MM) of the anal region is an uncommon disease.

Owing to delayed diagnosis and early metastases, the prognosis is often poor.

Anorectal melanomas (AM) are most common in the rectum, followed by the anal canal and anal verge.

The diagnosis of an AM is usually made using a biopsy.

Adjuvant immunohistological markers are the calcium-binding protein S-100, the melanoma antigen HMB-45, the melanoma-expressed protein Melan A, and microphthalmia-associated transcription factor (MiTF).

We report on a 39-year old man who presented with a 5-week history of recurrent prolapse of an anal tumour.

The tumour was histologically confirmed to be malignant melanoma.

[MeSH-major] Anus Neoplasms. Melanoma

[MeSH-minor] Adult. Angiogenesis Inhibitors / therapeutic use. Cancer Vaccines / therapeutic use. Diagnosis, Differential. Humans. Interferon-alpha / therapeutic use. Male. Prognosis. Treatment Outcome

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17376215.001).

[ISSN] 0307-6938

[Journal-full-title] Clinical and experimental dermatology

[ISO-abbreviation] Clin. Exp. Dermatol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Cancer Vaccines; 0 / Interferon-alpha

[Number-of-references] 25

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Primary melanoma of the rectum: an infrequent neoplasia with an atypical presentation].

[Transliterated title] Melanoma primario de recto: una neoplasia infrecuente con una forma de presentación atípica.

Primary anorectal melanoma is a rare malignancy with an extremely aggressive biological behaviour.

The main clinical presentations are local symptoms such as rectal bleeding, anal mass or pain, or a change in bowel habits.

[MeSH-major] Melanoma / diagnosis. Rectal Neoplasms / diagnosis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15960927.001).

[ISSN] 1699-048X

[Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

[ISO-abbreviation] Clin Transl Oncol

[Language] spa

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Spain

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Anal and anal margin tumors].

Tumors of the anal canal and anal margin are rare.

The other malignant tumors are very rare.

[MeSH-major] Anus Neoplasms / pathology

[MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Endocrine Gland Neoplasms / epidemiology. Endocrine Gland Neoplasms / pathology. France / epidemiology. Humans. Incidence. Leiomyosarcoma / pathology. Lymphoma / pathology. Melanoma / epidemiology. Melanoma / pathology. Papilloma / pathology. Sarcoma, Kaposi / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18554556.001).

[ISSN] 0242-6498

[Journal-full-title] Annales de pathologie

[ISO-abbreviation] Ann Pathol

[Language] fre

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] France

[Number-of-references] 110

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anal neoplasms.

A variety of lesions comprise tumors of the anal canal, with carcinoma in situ and epidermoid cancers being the most common.

Less common anal neoplasms include adenocarcinoma, melanoma, gastrointestinal stromal cell tumors, neuroendocrine tumors, and Buschke-Lowenstein tumors.

In this article different tumors and management of each, including a brief review of local excision for rectal cancer, are discussed in turn.

[MeSH-major] Anus Neoplasms / surgery

[MeSH-minor] Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Verrucous / diagnosis. Carcinoma, Verrucous / pathology. Humans. Intestinal Mucosa / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Rectal Neoplasms / surgery

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2010 Elsevier Inc. All rights reserved.

(PMID = 20109639.001).

[ISSN] 1558-3171

[Journal-full-title] The Surgical clinics of North America

[ISO-abbreviation] Surg. Clin. North Am.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 105

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Anal canal melanoma-- case report].

Anal canal melanoma is a rare disease comprising 1% of all colorectal ie. anal malignant tumours with very poor long term prognosis.

At the moment of diagnosis even 30% of the patients have distant metastases.

Modern approach to the anal canal melanoma treatment implies two types of intervention: wide local excision preserving the sphincter mechanism and abdominoperineal resection of the rectum.

The authors report on a 61 years old women in which anal canal melanoma with left inguinal lymphatic metastases was detected during the inspection of "haemorrhoids".

After the diagnosis was established, abdominoperineal resection of the rectum was performed with dissection of both inguinal regions.

[MeSH-major] Anus Neoplasms. Melanoma

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17338206.001).

[ISSN] 0354-950X

[Journal-full-title] Acta chirurgica Iugoslavica

[ISO-abbreviation] Acta Chir Iugosl

[Language] srp

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Serbia and Montenegro

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] An update on tumors of the anal canal.

CONTEXT: The anal canal possesses complex anatomy and histology and gives rise to a variety of tumor types.

Challenging issues remain with regard to both the pathologic diagnosis and the clinical management of these tumors.

OBJECTIVES: To provide an updated overview of the histogenesis, clinical and pathologic characteristics, diagnostic terminology, and relevant clinical management of the various types of anal canal tumors.

DATA SOURCES: Recent literature on clinical and pathologic characteristics of anal canal tumors.

CONCLUSIONS: Although most anal canal tumors are of squamous lineage, a complex variety of other tumors also occurs.

Recognition of such diverse tumor entities will allow accurate pathologic diagnosis and most optimal clinical management.

[MeSH-major] Adenocarcinoma / pathology. Anal Canal / pathology. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Melanoma / pathology

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21043813.001).

[ISSN] 1543-2165

[Journal-full-title] Archives of pathology & laboratory medicine

[ISO-abbreviation] Arch. Pathol. Lab. Med.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.

Recently 12 cases of metastatic melanoma and KIT-activating mutations have been published to be successfully treated with c-KIT blockers such as imatinib, sunitinib, dasatinib or sorafenib.

We report here on one of our patients with KIT-activating mutation in metastatic anal mucosal melanoma, who showed a response to imatinib therapy and summarize the available literature regarding this new therapeutic option.

[MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Melanoma / drug therapy. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Skin Neoplasms / pathology

MedlinePlus Health Information. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

Hazardous Substances Data Bank. IMATINIB MESYLATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2009 S. Karger AG, Basel.

(PMID = 19996579.001).

[ISSN] 1421-9832

[Journal-full-title] Dermatology (Basel, Switzerland)

[ISO-abbreviation] Dermatology (Basel)

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] Switzerland

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit

[Number-of-references] 18

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Diagnostic problems in anal pathology.

Anal squamous cell carcinoma and its precursor lesions are increasing in incidence in the United States and Europe.

Screening protocols for at-risk patients are under active investigation and pathologists are often asked to assess anal canal and perianal biopsies for the presence of dysplasia and/or invasive carcinoma.

Because underdiagnosis and overdiagnosis of anal cancer and precancer may lead to inappropriate treatment, it is important for the pathologist to be aware of current screening strategies, specific risk lesions, and the role of pathology in initial diagnosis and evaluation of anal biopsy and/or resection specimens.

Standardized histologic criteria and uniform terminology should be used for reporting all anal canal and perianal squamous intraepithelial lesions.

HPV subtyping, anal cytology, and recently identified biomarkers, such as p16 and Becton Dickinson ProEx C may provide additional information in problematic cases, but it is important to be aware of the limitations of these assays.

HPV has been linked to all the major histologic subtypes of anal carcinoma (eg, basaloid, cloacogenic, transitional, etc.) and this association is strongest for anal canal lesions.

With the possible exception of the microcystic pattern, histologic subtype does not seem to predict prognosis; and anal squamous cell carcinomas should be classified as either keratinizing or nonkeratinizing.

Poorly differentiated squamous cell carcinomas have a worse prognosis and should be distinguished from poorly differentiated adenocarcinoma, melanoma, and neuroendocrine tumors.

As all anal condylomata may harbor foci of high-grade dysplasia or invasive carcinoma, careful sectioning and complete histologic examination is required.

[MeSH-major] Anal Canal / pathology. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology

[MeSH-minor] Carcinoma, Verrucous / pathology. Condylomata Acuminata / pathology. Diagnosis, Differential. Humans. Papillomaviridae / genetics. Risk Factors. Terminology as Topic

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18724100.001).

[ISSN] 1533-4031

[Journal-full-title] Advances in anatomic pathology

[ISO-abbreviation] Adv Anat Pathol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 73

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.

DIAGNOSIS: Stage IV M1b metastatic anal mucosal melanoma.

[MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / therapy. Benzenesulfonates / therapeutic use. Melanoma / therapy. Pyridines / therapeutic use

MedlinePlus Health Information. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - Melanoma.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. DACARBAZINE .

Hazardous Substances Data Bank. NICOTINAMIDE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18936790.001).

[ISSN] 1743-4262

[Journal-full-title] Nature clinical practice. Oncology

[ISO-abbreviation] Nat Clin Pract Oncol

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P30 CA016672

[Publication-type] Case Reports; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy.

A retrospective study of anal sac tumours without pulmonary metastases, from the author's clinical records for the period July 1989 to July 2002, was conducted to establish the response to treatment with surgery and melphalan chemotherapy.

Of 21 dogs with tumours of the anal sacs 19 had apocrine gland adenocarcinomas of anal sac origin, one had a benign papillary cystadenoma and another had a malignant melanoma.

Two of the 19 dogs had bilateral anal sac adenocarcinomas.

Ten of the 19 dogs with apocrine gland adenocarcinomas of anal sac origin had sublumbar lymphadenopathy.

Fourteen dogs with apocrine gland adenocarcinomas of anal sac origin were treated by surgical cytoreduction and chemotherapy with melphalan.

Cytoreduction was by local excision of the anal sac in all 14 dogs and concurrent removal of the sublumbar retroperitoneal lymph nodes in the seven dogs with regional lymph node metastases.

The median survival time of dogs with sublumbar nodal metastasis was 20 months and for dogs with tumour localised to the anal sac the median survival time was 29.3 months.

This study suggests there is a role for melphalan in the treatment of dogs with anal sac adenocarcinoma when combined with cytoreductive surgery, with treatment survival times and the local recurrence rate of the primary tumour comparing favourably with previously published treatment regimes.

[MeSH-major] Anal Gland Neoplasms / epidemiology. Anal Sacs. Dog Diseases / epidemiology

[MeSH-minor] Adenocarcinoma / veterinary. Animals. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Cystadenoma, Papillary / veterinary. Dogs. Female. Male. Melanoma / veterinary. Neoplasm Metastasis. Records as Topic / veterinary. Retrospective Studies. Survival Analysis. Victoria / epidemiology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15986909.001).

[ISSN] 0005-0423

[Journal-full-title] Australian veterinary journal

[ISO-abbreviation] Aust. Vet. J.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Australia

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Clinical analysis of anorectal malignant melanoma].

OBJECTIVE: To summarize the clinicopathological characteristics of primary anorectal malignant melanoma (AMM).

RESULTS: Anorectal malignant melanoma had a female predominance.

The onset of symptom was hematochezia, then anus prolapses.

94.7% of patients had AMM within 5 cm from anus margin; the average tumor size was (3.3+/- 2.1) cm.

Mile's operation was performed in most of patients (63%), while anal resection was performed in 30% of the patients.

CONCLUSIONS: Anorectal malignant melanoma is often misdiagnosed,surgical procedure is the first choice for patients with AMM.

[MeSH-major] Anus Neoplasms / pathology. Melanoma / pathology. Rectal Neoplasms / pathology

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16167248.001).

[ISSN] 1671-0274

[Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery

[ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Melanoma of the small intestine.

Intestinal melanomas can be primary tumours or metastases of cutaneous, ocular, or anal melanomas.

Primary intestinal melanoma is extremely rare, whereas metastatic melanoma of the small bowel is common because of the tendency for cutaneous melanoma to metastasise to the gastrointestinal tract.

Because distinguishing between primary and metastatic intestinal melanoma can be difficult, the main features of each are discussed, and the diagnostic images used to detect intestinal melanoma are assessed.

Routine barium examinations and CT have limited sensitivity, but PET imaging can improve detection of melanoma metastases to the small bowel.

Although various treatment strategies have been tried in patients with intestinal melanoma, surgical removal of intestinal metastases is the treatment of choice in patients with resectable tumours.

No systemic therapy improves survival in patients with melanoma metastatic to the intestines; thus, the prognosis for these patients is poor.

Patients with primary melanoma of the small intestine have a worse prognosis than do patients with metastases of cutaneous melanoma.

[MeSH-major] Intestinal Neoplasms. Intestine, Small. Melanoma

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19410196.001).

[ISSN] 1474-5488

[Journal-full-title] The Lancet. Oncology

[ISO-abbreviation] Lancet Oncol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Number-of-references] 49

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Case report of primary rectal melanoma and review of the etiology of melanoma.

BACKGROUND: Primary rectal melanoma is a very rare and aggressive malignancy.

It is defined as melanoma arising in the rectal mucosa, more than 4 cm from the anal verge.

OBJECTIVE: A case of primary rectal melanoma is reported, and the theories of the etiology of melanoma are reviewed.

After immunohistochemical staining and microscopic examination, it was diagnosed as melanoma.

CONCLUSION: In light of primary melanoma in sun-shielded regions such as the rectum, theories of causation other than sun exposure merit consideration.

Factors such as genetics, immunosuppression, and virus infections, as well as ultraviolet radiation, may play a role in the etiology of melanoma.

[MeSH-major] Melanoma / diagnosis. Rectal Neoplasms / diagnosis

[MeSH-minor] Aged. Colonoscopy. Diagnosis, Differential. Female. Humans. Immunohistochemistry

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18544294.001).

[ISSN] 1203-4754

[Journal-full-title] Journal of cutaneous medicine and surgery

[ISO-abbreviation] J Cutan Med Surg

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Number-of-references] 16

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Variability in melanoma metalloproteinase expression profiling.

In the present study, RNA was isolated from multiple normal fibroblast and metastatic melanoma cell lines, as well as the isogenic normal tissue and tumor samples, and the gene expression levels of six ADAMs, eight MMPs, and four ADAMTSs were analyzed by real-time PCR.

Increased gene expression of several ADAM and MMP family members (MMP1, MMP8, MMP15, and ADAM15) occurred in melanoma tissue and was replicated in tissue cultures.

Passage-dependent expression patterns were observed for MMP8 and MMP9 in in-house-derived metastatic melanoma cell lines.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Protein Expr Purif. 2001 Feb;21(1):65-70 [11162388.001]

[Cites] In Vivo. 2001 Jan-Feb;15(1):57-64 [11286131.001]

[Cites] Am J Clin Pathol. 2001 Apr;115(4):517-24 [11293899.001]

[Cites] Eur J Dermatol. 2001 Sep-Oct;11(5):420-3 [11525948.001]

[Cites] Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15 [11597399.001]

[Cites] Matrix Biol. 2001 Dec;20(8):577-87 [11731274.001]

[Cites] J Biol Chem. 2001 Dec 14;276(50):47402-10 [11584019.001]

[Cites] Int J Cancer. 2002 Feb 1;97(4):432-8 [11802203.001]

[Cites] J Exp Med. 2002 Feb 4;195(3):295-308 [11828004.001]

[Cites] Gene. 2002 Jan 23;283(1-2):49-62 [11867212.001]

[Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]

[Cites] J Pathol. 2002 Jun;197(2):179-87 [12015741.001]

[Cites] Clin Chem. 2002 Aug;48(8):1170-7 [12142369.001]

[Cites] J Biol Chem. 2002 Aug 30;277(35):32360-8 [12060661.001]

[Cites] Differentiation. 2002 Dec;70(9-10):486-97 [12492491.001]

[Cites] Curr Opin Cell Biol. 2003 Oct;15(5):598-606 [14519395.001]

[Cites] Cell Biochem Funct. 2003 Dec;21(4):381-6 [14624478.001]

[Cites] Annu Rev Pharmacol Toxicol. 2004;44:195-217 [14744244.001]

[Cites] J Cell Biol. 2004 Mar 1;164(5):769-79 [14993236.001]

[Cites] Cancer Res. 2004 Mar 15;64(6):2062-9 [15026344.001]

[Cites] Bioinformatics. 2004 Oct 12;20(15):2471-2 [15073005.001]

[Cites] Hum Pathol. 1984 Dec;15(12):1147-65 [6500548.001]

[Cites] Mol Cell Proteomics. 2007 Apr;6(4):611-23 [17200105.001]

[Cites] Cancer Sci. 2007 May;98(5):621-8 [17355265.001]

[Cites] Nature. 2007 Apr 12;446(7137):765-70 [17429393.001]

[Cites] Melanoma Res. 2007 Aug;17(4):205-13 [17625450.001]

[Cites] Pigment Cell Res. 2007 Dec;20(6):466-84 [17935490.001]

[Cites] Differentiation. 2007 Nov;75(9):800-8 [17608729.001]

[Cites] Cancer Res. 2007 Nov 15;67(22):10849-58 [18006830.001]

[Cites] J Biol Chem. 2007 Dec 7;282(49):35712-21 [17895248.001]

[Cites] J Cell Sci. 1990 Oct;97 ( Pt 2):373-83 [2177480.001]

[Cites] Nature. 1994 Jul 7;370(6484):61-5 [8015608.001]

[Cites] Int J Cancer. 1996 Jan 17;65(2):209-13 [8567119.001]

[Cites] J Biol Chem. 1996 Jul 19;271(29):17124-31 [8663255.001]

[Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7069-74 [8692946.001]

[Cites] J Pathol. 1996 Nov;180(3):283-9 [8958806.001]

[Cites] Nature. 1997 Feb 20;385(6618):729-33 [9034190.001]

[Cites] Crit Rev Eukaryot Gene Expr. 1997;7(1-2):159-78 [9034720.001]

[Cites] Clin Exp Metastasis. 1997 Mar;15(2):111-20 [9062387.001]

[Cites] J Cell Biol. 1997 Apr 7;137(1):67-77 [9105037.001]

[Cites] Matrix Biol. 1997 Mar;15(8-9):519-26 [9138284.001]

[Cites] Cancer Res. 1997 May 15;57(10):2055-60 [9158005.001]

[Cites] Curr Opin Oncol. 1997 Mar;9(2):178-82 [9161798.001]

[Cites] J Biol Chem. 1997 Sep 26;272(39):24588-93 [9305925.001]

[Cites] J Cell Physiol. 1997 Nov;173(2):275-8 [9365536.001]

[Cites] Eur J Biochem. 1997 Dec 15;250(3):751-7 [9461298.001]

[Cites] Pathobiology. 1997;65(6):311-30 [9491851.001]

[Cites] Biochem Biophys Res Commun. 1998 Apr 17;245(2):594-8 [9571200.001]

[Cites] J Pathol. 1998 Sep;186(1):51-8 [9875140.001]

[Cites] Am J Pathol. 1999 Feb;154(2):417-28 [10027400.001]

[Cites] FASEB J. 1999 May;13(8):781-92 [10224222.001]

[Cites] Am J Pathol. 1999 May;154(5):1489-501 [10329602.001]

[Cites] J Urol. 1999 Sep;162(3 Pt 1):905-9 [10458406.001]

[Cites] J Biol Chem. 1999 Sep 3;274(36):25371-8 [10464264.001]

[Cites] J Biol Chem. 2004 Dec 3;279(49):51323-30 [15381692.001]

[Cites] J Cancer Res Clin Oncol. 2005 Jan;131(1):41-8 [15565459.001]

[Cites] Int J Oncol. 2005 Jan;26(1):17-24 [15586220.001]

[Cites] J Biol Chem. 2005 Jan 21;280(3):1826-37 [15507448.001]

[Cites] Biochem J. 2005 Feb 15;386(Pt 1):15-27 [15554875.001]

[Cites] Int J Cancer. 2005 Apr 20;114(4):544-54 [15551360.001]

[Cites] Cancer Res. 2005 May 15;65(10):4134-46 [15899804.001]

[Cites] Int J Cancer. 2005 Oct 10;116(6):853-9 [15856464.001]

[Cites] Clin Exp Metastasis. 2005;22(4):285-95 [16170665.001]

[Cites] Front Biosci. 2006;11:1199-215 [16368506.001]

[Cites] Toxicology. 2006 Feb 1;218(2-3):205-15 [16337326.001]

[Cites] Exp Cell Res. 2006 Mar 10;312(5):608-22 [16442099.001]

[Cites] J Cell Sci. 2006 Apr 15;119(Pt 8):1477-82 [16551697.001]

[Cites] BMC Cancer. 2006;6:52 [16515711.001]

[Cites] Matrix Biol. 2007 Oct;26(8):587-96 [17669641.001]

[Cites] Biochimie. 2008 Feb;90(2):369-79 [17920749.001]

[Cites] Hum Pathol. 2008 Mar;39(3):337-43 [18045645.001]

[Cites] Hum Pathol. 2008 Mar;39(3):377-85 [18187184.001]

[Cites] J Allergy Clin Immunol. 2008 Jun;121(6):1400-6, 1406.e1-4 [18410963.001]

[Cites] Anal Biochem. 2008 Sep 1;380(1):137-9 [18554498.001]

[Cites] Mol Cell Biol. 2008 Aug;28(15):4896-914 [18505826.001]

[Cites] Mol Aspects Med. 2008 Oct;29(5):290-308 [18619669.001]

[Cites] FEBS Lett. 1997 Jan 6;400(3):333-5 [9009225.001]

[Cites] Nat Genet. 2009 May;41(5):518-20 [19330028.001]

[Cites] Int J Cancer. 2009 Oct 15;125(8):1796-804 [19569239.001]

[Cites] J Invest Dermatol. 2009 Nov;129(11):2686-93 [19516266.001]

[Cites] J Biol Chem. 2009 Nov 13;284(46):31493-7 [19734141.001]

[Cites] BMC Cancer. 2009;9:20 [19144199.001]

[Cites] Clin Chim Acta. 2000 Feb 15;291(2):113-35 [10675719.001]

[Cites] J Clin Oncol. 2000 Mar;18(5):1135-49 [10694567.001]

[Cites] J Cell Biol. 2000 May 29;149(5):1143-56 [10831617.001]

[Cites] J Invest Dermatol. 2000 Sep;115(3):337-44 [10951266.001]

(PMID = 21119930.001).

[ISSN] 1943-4731

[Journal-full-title] Journal of biomolecular techniques : JBT

[ISO-abbreviation] J Biomol Tech

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA098799; United States / NIDCR NIH HHS / DE / T32 DE014318; United States / NCI NIH HHS / CA / CA98799; United States / NIDCR NIH HHS / DE / DE14318

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / RNA, Messenger; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / Matrix Metalloproteinases

[Other-IDs] NLM/ PMC2977965

[Keywords] NOTNLM ; ADAM / MMP / tissue

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Is sentinel node mapping useful in anorectal melanoma?

Anorectal melanoma (AM) is a rare disease and few guidelines have been established regarding its therapeutic management.

Under rigid proctoscopy the anal scar received four submucosal injections of technetium-99m-sulfur nanocolloid of 29.6 MBq each.

[MeSH-major] Lymph Nodes / pathology. Lymph Nodes / radionuclide imaging. Melanoma / radionuclide imaging. Melanoma / secondary. Rectal Neoplasms / pathology. Rectal Neoplasms / radionuclide imaging. Sentinel Lymph Node Biopsy / methods. Technetium Tc 99m Aggregated Albumin

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18392226.001).

[ISSN] 1790-5427

[Journal-full-title] Hellenic journal of nuclear medicine

[ISO-abbreviation] Hell J Nucl Med

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Greece

[Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Technetium Tc 99m Aggregated Albumin; 0 / technetium Tc 99m nanocolloid

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Anal cancer in Iceland 1987-2003. A population based study].

OBJECTIVE: Anal cancer is a rare disease.

The aim of this study was to describe anal cancer in Iceland in 1987-2003 with respect to incidence, histologic type, treatment, recurrence rate and survival.

MATERIAL AND METHODS: This is a retrospective study in which all malignant anal tumours diagnosed in Iceland in the period 1987-2003 were reviewed with respect to patient outcome.

This is a nationwide, population-based study of malignant tumours of the anal region.

RESULTS: From 1987-2003 thirty-eight patients were diagnosed with anal cancer, 28 females and 10 males.

The average age at diagnosis was 63.4 years.

Age standardized incidence rates for anal cancer in Iceland were 0.3 (+/-0.2) of 100.000 males and 0.9 (+/-0.4) of 100.000 females.

The remaining histologic types were malignant melanoma (n=3), adenosquamous carcinoma (n=1), adenocarcinoma (n=1), GIST (n=1) and undifferentiated carcinoma (n=2).

The duration of symptoms before diagnosis ranged from 2 weeks to 96 months (mean value 3.5 months).

Twelve patients had recurrent cancer.

The mean value of the time from diagnosis of the primary to the recurrent cancer was 15.6 months (range, 5.9-117).

Sixteen patients remain with disease and ten have died of anal cancer.

The five year survival rate for patients diagnosed in the years 1987 to 1998 is 75% but cancer-specific survival is 82%.

CONCLUSION: Age-standardized incidence for anal cancer in Iceland is similar to other regions.

Average age at diagnosis, male-female ratio and prognosis is similar to reports in other studies.

The proportion of adenocarcinoma of the anus is lower in Iceland than elsewhere.

[MeSH-major] Anus Neoplasms / epidemiology

[MeSH-minor] Adenocarcinoma / epidemiology. Aged. Carcinoma / epidemiology. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Squamous Cell / epidemiology. Defecation. Female. Gastrointestinal Hemorrhage / etiology. Humans. Iceland / epidemiology. Incidence. Male. Melanoma / epidemiology. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pain / etiology. Pruritus / epidemiology. Retrospective Studies. Survival Analysis

Genetic Alliance. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16741319.001).

[ISSN] 0023-7213

[Journal-full-title] Læknablađiđ

[ISO-abbreviation] Laeknabladid

[Language] ice

[Publication-type] English Abstract; Journal Article

[Publication-country] Iceland

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A striking response of anorectal melanoma to radiotherapy (locoregional disease confined to perineum and anal canal).

Anorectal melanoma is a rare disease with an exceedingly poor prognosis.

Literature evaluating outcomes is often difficult because of the infrequent diagnosis, delayed presentation and almost universally poor outcome.

We describe a case of a 78-year-old woman with a large anorectal melanoma without detectable metastasis following radiological investigation.

This is the first case of the successful use of radiotherapy alone in anorectal melanoma.

[MeSH-major] Melanoma / radiotherapy. Rectal Neoplasms / radiotherapy

[MeSH-minor] Aged. Anus Neoplasms / radiotherapy. Female. Humans. Perineum. Remission Induction. Treatment Outcome

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20056049.001).

[ISSN] 1478-7083

[Journal-full-title] Annals of the Royal College of Surgeons of England

[ISO-abbreviation] Ann R Coll Surg Engl

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Importance of clear resection margins in anorectal malignant melanoma.

BACKGROUND: Anorectal melanoma is rare and surgery is the recommended primary treatment.

METHODS: From the Swedish National Cancer Registry, 251 patients with anorectal melanoma were identified from 1960 to 1999.

CONCLUSION: Both APR and LE seem appropriate for anorectal melanoma provided clear margins can be achieved; prognosis is poor regardless of surgical approach.

[MeSH-major] Anal Canal / surgery. Anus Neoplasms / surgery. Melanoma / surgery. Rectal Neoplasms / surgery. Rectum / surgery

MedlinePlus Health Information. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Melanoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

(PMID = 20013935.001).

[ISSN] 1365-2168

[Journal-full-title] The British journal of surgery

[ISO-abbreviation] Br J Surg

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] miR-148 regulates Mitf in melanoma cells.

The Microphthalmia associated transcription factor (Mitf) is an important regulator in melanocyte development and has been shown to be involved in melanoma progression.

The current model for the role of Mitf in melanoma assumes that the total activity of the protein is tightly regulated in order to secure cell proliferation.

Here we show that microRNAs (miRNAs) are also involved in regulating Mitf in melanoma cells.

Furthermore, miR-148 was shown to affect Mitf mRNA expression in melanoma cells through a conserved binding site in the 3'UTR sequence of mouse and human Mitf.

Our data show that miR-148 and miR-137 present an additional level of regulating Mitf expression in melanocytes and melanoma cells.

Loss of this regulation, either by mutations or by shortening of the 3'UTR sequence, is therefore a likely factor in melanoma formation and/or progression.

[MeSH-major] 3' Untranslated Regions / genetics. Melanoma / genetics. Melanoma / metabolism. MicroRNAs / genetics. MicroRNAs / metabolism. Microphthalmia-Associated Transcription Factor / genetics. Microphthalmia-Associated Transcription Factor / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]

[Cites] Dev Dyn. 1998 Nov;213(3):283-92 [9825864.001]

[Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]

[Cites] Nature. 2005 Feb 17;433(7027):764-9 [15716956.001]

[Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]

[Cites] Nature. 2005 Jul 7;436(7047):117-22 [16001072.001]

[Cites] Pigment Cell Res. 2005 Aug;18(4):265-77 [16029420.001]

[Cites] J Cell Biol. 2005 Aug 29;170(5):703-8 [16129781.001]

[Cites] J Biol Chem. 2006 Apr 14;281(15):10365-73 [16455654.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17337-42 [17085592.001]

[Cites] Genes Dev. 2006 Dec 15;20(24):3426-39 [17182868.001]

[Cites] Nat Chem Biol. 2007 Mar;3(3):166-73 [17259978.001]

[Cites] Cancer Res. 2007 Mar 15;67(6):2456-68 [17363563.001]

[Cites] Nat Protoc. 2006;1(3):1559-82 [17406449.001]

[Cites] Nucleic Acids Res. 2007;35(7):2333-42 [17389647.001]

[Cites] Pigment Cell Res. 2007 Jun;20(3):185-200 [17516926.001]

[Cites] BMC Genomics. 2007;8:152 [17555584.001]

[Cites] J Biol Chem. 2007 Aug 24;282(34):25053-66 [17597072.001]

[Cites] J Pathol. 2008 Jan;214(1):17-24 [17948228.001]

[Cites] Cancer Res. 2008 Mar 1;68(5):1362-8 [18316599.001]

[Cites] Cancer Res. 2008 Apr 1;68(7):2094-105 [18381414.001]

[Cites] RNA. 2008 May;14(5):872-7 [18367714.001]

[Cites] BMC Med. 2008;6:14 [18577219.001]

[Cites] Genes Dev. 2008 Nov 15;22(22):3172-83 [19056895.001]

[Cites] Int J Oncol. 2009 Feb;34(2):537-42 [19148490.001]

[Cites] Hum Mol Genet. 2000 Jan 1;9(1):125-32 [10587587.001]

[Cites] Cell Mol Biol (Noisy-le-grand). 1999 Nov;45(7):1075-82 [10644012.001]

[Cites] Genes Dev. 2000 Feb 1;14(3):301-12 [10673502.001]

[Cites] Annu Rev Genet. 2004;38:365-411 [15568981.001]

[Cites] Cancer Cell. 2004 Dec;6(6):565-76 [15607961.001]

[Cites] J Biol Chem. 2005 Jan 7;280(1):146-55 [15507434.001]

[Cites] J Cell Biol. 2005 Jan 3;168(1):35-40 [15623583.001]

[Cites] Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1814-9 [19188590.001]

[Cites] J Invest Dermatol. 2009 Jul;129(7):1740-51 [19212343.001]

[Cites] J Dig Dis. 2009 Aug;10(3):188-94 [19659786.001]

[Cites] Br J Cancer. 2009 Aug 18;101(4):551-6 [19638982.001]

[Cites] Cell. 2009 Aug 21;138(4):673-84 [19703394.001]

[Cites] Int J Cancer. 2009 Dec 1;125(11):2737-43 [19521961.001]

[Cites] J Biol Chem. 2010 Jul 2;285(27):20532-40 [20439467.001]

[Cites] Invest Ophthalmol Vis Sci. 2007 Sep;48(9):3962-7 [17724173.001]

[Cites] Exp Cell Res. 2000 Mar 15;255(2):135-43 [10694430.001]

[Cites] Am J Hum Genet. 2000 Aug;67(2):345-56 [10889045.001]

[Cites] J Biol Chem. 2000 Jul 21;275(29):21920-7 [10770922.001]

[Cites] Development. 2000 Aug;127(16):3581-91 [10903182.001]

[Cites] J Invest Dermatol. 2001 Dec;117(6):1505-11 [11886515.001]

[Cites] J Biol Chem. 2002 Mar 29;277(13):11077-83 [11792706.001]

[Cites] Cancer Res. 2002 Apr 1;62(7):2098-103 [11929831.001]

[Cites] Curr Biol. 2002 Apr 30;12(9):735-9 [12007417.001]

[Cites] Cell. 2002 Jun 14;109(6):707-18 [12086670.001]

[Cites] Cell. 2003 Dec 26;115(7):787-98 [14697198.001]

[Cites] Genes Dev. 2004 Jan 15;18(2):132-7 [14729570.001]

[Cites] Genome Biol. 2004;5(3):R13 [15003116.001]

[Cites] Genes Dev. 2004 Mar 1;18(5):504-11 [15014042.001]

[Cites] Science. 2004 Apr 23;304(5670):594-6 [15105502.001]

[Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]

[Cites] Cell. 1993 Jul 30;74(2):395-404 [8343963.001]

[Cites] J Biol Chem. 1993 Oct 5;268(28):20687-90 [8407885.001]

[Cites] Genes Dev. 1994 Nov 15;8(22):2770-80 [7958932.001]

[Cites] Mol Cell Biol. 1994 Dec;14(12):8058-70 [7969144.001]

[Cites] Nature. 1998 Jan 15;391(6664):298-301 [9440696.001]

[Cites] Mech Dev. 1998 Jan;70(1-2):155-66 [9510032.001]

[Cites] Science. 2005 Feb 4;307(5710):720-4 [15618488.001]

(PMID = 20644734.001).

[ISSN] 1932-6203

[Journal-full-title] PloS one

[ISO-abbreviation] PLoS ONE

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / MicroRNAs; 0 / Microphthalmia-Associated Transcription Factor

[Other-IDs] NLM/ PMC2904378

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Rectal melanoma--a rare tumour.

Malignant rectal melanoma is a rare tumour.

Biopsies proved it to be an amelanotic malignant melanoma, as protein S100, melanoma antigen HMB45 and Melan-A expression were found.

An abdominoperineal resection was performed as a substantial part of the internal anal sphincter was invaded.

Histology confirmed an amelanotic malignant melanoma.

With this case we want to illustrate that malignant rectal melanoma can be difficult to diagnose, as patients have non-specific symptoms, and histology may be misleading.

One should always check for protein S-100, melanoma antigen HMN-45 and Melan-A expression, as they are strongly suggestive of melanoma.

Wide local excision is the preferred procedure when technically feasible, but abdominoperineal resection has to be done if the tumour invades a substantial portion of the anal sphincter or is circumferential.

Rectal melanoma has a poor outcome with a 5-year survival rate of between 10-20%.

[MeSH-major] Melanoma, Amelanotic / surgery. Rectal Neoplasms / surgery

[MeSH-minor] Aged. Anal Canal / pathology. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Male. Neoplasm Invasiveness. Prognosis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19241934.001).

[ISSN] 0001-5458

[Journal-full-title] Acta chirurgica Belgica

[ISO-abbreviation] Acta Chir. Belg.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Belgium

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Late recurrence of malignant melanoma in the duodenum.

Melanoma is a malignancy originating from melanocytes.

The primary melanoma usually occurs on the skin, retina, anal canal or occasionally at other organs such as the esophagus, penis or vagina.

Although melanoma represents about one-third of all metastatic lesions in the gastrointestinal tract, metastasis of melanoma to the GI tract, detected radiologically or endoscopically, is relatively rare.

In most cases of malignant melanoma, recurrence and death occur within 10 years after treatment of the primary lesion.

We herein report a case showing a recurrence 17 years after extirpation of primary malignant melanoma in the foot.

A 65-year-old man, with a history of extirpation of a malignant melanoma in the sole of his foot 17 years before, presented with anorexia and severe anemia, and multiple duodenal tumors were pointed out with upper gastrointestinal endoscopy.

Histologic examination of the endoscopic biopsy specimen revealed proliferation of large polygonal cells with distinct nucleoli, and malignant melanoma was diagnosed immunohistochemically.

[MeSH-major] Duodenal Neoplasms / pathology. Melanoma / pathology. Neoplasm Recurrence, Local / pathology

MedlinePlus Health Information. consumer health - Intestinal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19102354.001).

[ISSN] 0172-6390

[Journal-full-title] Hepato-gastroenterology

[ISO-abbreviation] Hepatogastroenterology

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Greece

[Chemical-registry-number] 0 / CC chemokine receptor 9; 0 / Receptors, CCR

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Gastrointestinal melanoma or clear cell sarcoma? Molecular evaluation of 7 cases previously diagnosed as malignant melanoma.

CCS and malignant melanoma (MM) share immunohistochemical profiles and ultrastructural features, but classic CCS has characteristic morphology with low mitotic activity and minimal pleomorphism.

This translocation has never been documented in cutaneous melanoma, and thus is regarded as specific for CCS.

Recent evidence suggests that primary "malignant melanomas" in unusual anatomic sites, most notably the gastrointestinal (GI) tract, may be CCS.

In total, we examined 7 cases: Four with no prior history of MM, 2 with histories of cutaneous MM, and 1 with an anal MM.

[MeSH-major] Gastrointestinal Neoplasms / diagnosis. Melanoma / diagnosis. Sarcoma, Clear Cell / diagnosis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18408594.001).

[ISSN] 1532-0979

[Journal-full-title] The American journal of surgical pathology

[ISO-abbreviation] Am. J. Surg. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma.

Melanoma and other cancers harbor oncogenic mutations in the protein kinase B-Raf, which leads to constitutive activation and dysregulation of MAP kinase signaling.

In order to elucidate molecular determinants responsible for B-Raf control of cancer phenotypes, we present a method for phosphoprotein profiling, using negative ionization mass spectrometry to detect phosphopeptides based on their fragment ion signature caused by release of PO(3)(-).

Ninety phosphorylation events were regulated by oncogenic B-Raf signaling, based on their responses to treating melanoma cells with MKK1/2 inhibitor.

We investigated MINERVA/FAM129B, a target belonging to a protein family with unknown category and function, and established the importance of this protein and its MAP kinase-dependent phosphorylation in controlling melanoma cell invasion into three-dimensional collagen matrix.

MedlinePlus Health Information. consumer health - Melanoma.

COS Scholar Universe. author profiles.

PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Anal Chem. 2004 Jul 1;76(13):3556-68 [15228325.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12130-5 [15302935.001]

[Cites] J Biol Chem. 1989 Dec 5;264(34):20518-25 [2511205.001]

[Cites] Biochem J. 1994 Nov 1;303 ( Pt 3):701-4 [7980435.001]

[Cites] Anal Biochem. 1996 Aug 1;239(2):180-92 [8811904.001]

[Cites] EMBO J. 1997 Nov 3;16(21):6439-51 [9351826.001]

[Cites] J Biol Chem. 1998 Jan 16;273(3):1496-505 [9430688.001]

[Cites] Nat Struct Mol Biol. 2004 Dec;11(12):1192-7 [15543157.001]

[Cites] Oncogene. 2005 May 12;24(21):3459-71 [15735667.001]

[Cites] J Cell Biol. 2005 Aug 29;170(5):703-8 [16129781.001]

[Cites] Mol Cell Proteomics. 2005 Sep;4(9):1240-50 [15951569.001]

[Cites] Mol Cell Proteomics. 2005 Oct;4(10):1487-502 [15979981.001]

[Cites] J Exp Med. 2006 Jul 10;203(7):1651-6 [16801397.001]

[Cites] J Clin Oncol. 2006 Sep 10;24(26):4340-6 [16908931.001]

[Cites] Nat Biotechnol. 2006 Oct;24(10):1285-92 [16964243.001]

[Cites] Cell. 2006 Nov 3;127(3):635-48 [17081983.001]

[Cites] Mol Cell Proteomics. 2007 Jan;6(1):1-17 [17018520.001]

[Cites] Curr Biol. 2007 Jan 23;17(2):179-84 [17174095.001]

[Cites] Nature. 2007 Feb 22;445(7130):851-7 [17314971.001]

[Cites] Nat Methods. 2007 Mar;4(3):231-7 [17293869.001]

[Cites] Cancer Res. 2003 Feb 15;63(4):756-9 [12591721.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):183-8 [12518064.001]

[Cites] Cancer Res. 2002 Dec 1;62(23):6997-7000 [12460918.001]

[Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]

[Cites] Rapid Commun Mass Spectrom. 2001;15(17):1593-9 [11544598.001]

[Cites] Anal Chem. 2001 Apr 1;73(7):1440-8 [11321292.001]

[Cites] Methods Enzymol. 2001;332:417-31 [11305115.001]

[Cites] EMBO J. 2000 Jun 15;19(12):2924-34 [10856237.001]

[Cites] Mol Cancer Ther. 2006 May;5(5):1136-44 [16731745.001]

[Cites] Proteomics. 2004 Jun;4(6):1551-61 [15174125.001]

[Cites] Mol Cell Biol. 2004 Jun;24(12):5269-80 [15169891.001]

[Cites] Cell. 2004 Mar 19;116(6):855-67 [15035987.001]

[Cites] Mol Cell Biol. 2004 Apr;24(7):2923-31 [15024080.001]

[Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]

[Cites] Biochem J. 2004 Jan 1;377(Pt 1):249-55 [14570592.001]

[Cites] Leukemia. 2003 Aug;17(8):1605-12 [12886250.001]

[Cites] Cancer Res. 2003 Jul 15;63(14):3955-7 [12873990.001]

[Cites] Anal Chem. 2003 Apr 15;75(8):1895-904 [12713048.001]

[Cites] Cancer Lett. 2008 Jul 8;265(2):157-66 [18406052.001]

[Cites] Mol Cell Proteomics. 2006 Feb;5(2):337-46 [16260767.001]

[Cites] Cancer Res. 2007 Apr 1;67(7):3177-84 [17409425.001]

[Cites] Clin Cancer Res. 2007 Aug 15;13(16):4934-42 [17652623.001]

[Cites] Nat Chem Biol. 2005 Oct;1(5):252-62 [16408053.001]

[CommentIn] Mol Cell. 2009 Apr 24;34(2):139-40 [19394291.001]

(PMID = 19362540.001).

[ISSN] 1097-4164

[Journal-full-title] Molecular cell

[ISO-abbreviation] Mol. Cell

[Language] ENG

[Grant] United States / NCRR NIH HHS / RR / RR021005-01; United States / NIGMS NIH HHS / GM / GM065103-08; United States / NCI NIH HHS / CA / R01-CA126240; United States / NIGMS NIH HHS / GM / T32 GM008759; United States / NCI NIH HHS / CA / R01-CA118972; United States / NIGMS NIH HHS / GM / T32 GM065103-08; United States / NCRR NIH HHS / RR / S10 RR021005-01; United States / NCI NIH HHS / CA / R01 CA118972; United States / NCI NIH HHS / CA / R01 CA118972-02; United States / NCI NIH HHS / CA / R01 CA126240; United States / NCRR NIH HHS / RR / S10 RR021005; United States / NIGMS NIH HHS / GM / T32 GM065103

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Fam129B protein, human; 0 / Phosphoproteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf

[Other-IDs] NLM/ NIHMS111623; NLM/ PMC2735263

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Inhibition of melanoma angiogenesis by telomere homolog oligonucleotides.

We found that T-oligo-treated human melanoma (MM-AN) cells had decreased expression of vascular endothelial growth factor (VEGF), VEGF receptor 2, angiopoeitin-1 and -2 and decreased VEGF secretion.

In melanoma SCID xenografts, two systemic T-oligo injections decreased by 60% (P < .004) total tumor microvascular density and the functional vessels density by 80% (P < .002).

These findings suggest that restriction of tumor angiogenesis is among the host's innate telomere-based anticancer responses and provide further evidence that T-oligos may offer a powerful new approach for melanoma treatment.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Pathol. 2002 Jun;160(6):1937-9 [12057896.001]

[Cites] Oncogene. 1997 May 22;14(20):2475-83 [9188862.001]

[Cites] FASEB J. 2002 May;16(7):754-6 [11923222.001]

[Cites] Nucleic Acids Res. 2002 Apr 15;30(8):1859-67 [11937641.001]

[Cites] Oncogene. 2002 Jan 21;21(4):532-40 [11850778.001]

[Cites] Melanoma Res. 2001 Dec;11(6):639-43 [11725211.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10857-62 [11553814.001]

[Cites] FASEB J. 2001 Sep;15(11):1877-85 [11532967.001]

[Cites] Cancer Res. 2001 Aug 15;61(16):6248-54 [11507079.001]

[Cites] Genes Dev. 2001 Jul 15;15(14):1833-44 [11459832.001]

[Cites] J Dermatol Sci. 2001 Feb;25(2):127-38 [11164709.001]

[Cites] Mol Cell Biochem. 2000 Oct;213(1-2):145-53 [11129953.001]

[Cites] Oncogene. 2000 Jul 20;19(31):3470-6 [10918605.001]

[Cites] Oncol Rep. 2009 Jul;22(1):105-13 [19513511.001]

[Cites] FASEB J. 2007 Sep;21(11):2918-30 [17449721.001]

[Cites] Nature. 2007 Aug 30;448(7157):1068-71 [17687332.001]

[Cites] Curr Top Med Chem. 2007;7(14):1379-93 [17692027.001]

[Cites] Cell Signal. 2007 Oct;19(10):2003-12 [17658244.001]

[Cites] Circulation. 2007 Feb 13;115(6):752-62 [17261656.001]

[Cites] J Cell Physiol. 2007 Mar;210(3):582-95 [17133364.001]

[Cites] World J Gastroenterol. 2006 Nov 21;12(43):6941-8 [17109514.001]

[Cites] Cell Signal. 2006 Nov;18(11):2041-8 [16725311.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15073-8 [17015833.001]

[Cites] Cell. 1996 Dec 27;87(7):1161-9 [8980223.001]

[Cites] EMBO J. 1996 Apr 1;15(7):1734-41 [8612598.001]

[Cites] J Exp Med. 1994 Sep 1;180(3):1141-6 [8064230.001]

[Cites] Melanoma Res. 1993 Aug;3(4):247-53 [8219757.001]

[Cites] Histochemistry. 1987;86(6):603-7 [3610672.001]

[Cites] Basic Life Sci. 1975;5A:355-67 [1103845.001]

[Cites] Int J Dev Biol. 2004;48(5-6):563-71 [15349831.001]

[Cites] FASEB J. 2004 Sep;18(12):1373-81 [15333580.001]

[Cites] J Pathol. 2004 Sep;204(1):1-10 [15307132.001]

[Cites] Cancer Res. 2004 Jul 15;64(14):4833-40 [15256453.001]

[Cites] Mol Cell. 2004 Jun 18;14(6):763-74 [15200954.001]

[Cites] Cancer Res. 2004 Jun 1;64(11):3731-6 [15172975.001]

[Cites] J Biol Chem. 2003 Dec 19;278(51):51267-76 [14532277.001]

[Cites] Circulation. 2000 Jan 18;101(2):171-7 [10637205.001]

[Cites] Circ Res. 2003 Nov 14;93(10):932-40 [14576193.001]

[Cites] Microvasc Res. 2003 Mar;65(2):125-31 [12686170.001]

[Cites] FASEB J. 2003 Feb;17(2):152-62 [12554694.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):527-31 [12515865.001]

[Cites] FASEB J. 2006 Sep;20(11):1895-7 [16877521.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):11015-20 [16835303.001]

[Cites] FASEB J. 2006 Jul;20(9):1495-7 [16754748.001]

[Cites] Exp Cell Res. 2006 Mar 10;312(5):594-607 [16376330.001]

[Cites] Anal Chem. 2006 Mar 1;78(5):1478-84 [16503597.001]

[Cites] J Biol Chem. 2005 Sep 16;280(37):32379-88 [16046401.001]

[Cites] J Biol Chem. 2005 Aug 26;280(34):29993-30000 [15970595.001]

[Cites] Cancer Res. 2005 Feb 1;65(3):671-80 [15705858.001]

[Cites] Cardiovasc Res. 2005 Feb 15;65(3):564-73 [15664382.001]

[Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]

[Cites] Exp Cell Res. 2004 Dec 10;301(2):189-200 [15530855.001]

[Cites] Circ Res. 1998 Aug 10;83(3):233-40 [9710115.001]

[Cites] J Invest Dermatol. 1999 Jan;112(1):25-31 [9886259.001]

[Cites] Science. 1997 Jul 4;277(5322):55-60 [9204896.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12627-32 [9356500.001]

[Cites] Exp Cell Res. 2002 Jun 10;276(2):185-93 [12027448.001]

(PMID = 20652008.001).

[ISSN] 1687-8469

[Journal-full-title] Journal of oncology

[ISO-abbreviation] J Oncol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Egypt

[Other-IDs] NLM/ PMC2906154

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis.

PURPOSE: Intensity-modulated radiation therapy (IMRT) has the potential to reduce toxicities associated with chemoradiotherapy in the treatment of anal cancer.

This study reports the results of using IMRT in the treatment of anal cancer.

METHODS AND MATERIALS: Records of patients with anal malignancies treated with IMRT at Duke University were reviewed.

RESULTS: Forty-seven patients with anal malignancy (89% canal, 11% perianal skin) were treated with IMRT between August 2006 and September 2008.

CONCLUSIONS: IMRT-based chemoradiotherapy for anal cancer results in significant reductions in normal tissue dose and acute toxicities versus historic controls treated without IMRT, leading to reduced rates of toxicity-related treatment interruption.

IMRT is emerging as a standard therapy for anal cancer.

[MeSH-major] Anus Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / adverse effects

[MeSH-minor] Adenocarcinoma / radiotherapy. Adolescent. Adult. Aged. Aged, 80 and over. Anemia / etiology. Carcinoma, Squamous Cell / radiotherapy. Diarrhea / etiology. Female. Humans. Leukopenia / etiology. Male. Melanoma / radiotherapy. Middle Aged. Neuroendocrine Tumors / radiotherapy. Radiotherapy Dosage. Rhabdomyosarcoma / radiotherapy. Sarcoma / radiotherapy. Thrombocytopenia / etiology. Treatment Outcome. Young Adult

MedlinePlus Health Information. consumer health - Anal Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.

(PMID = 20231064.001).

[ISSN] 1879-355X

[Journal-full-title] International journal of radiation oncology, biology, physics

[ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Proteomic analysis of laser microdissected melanoma cells from skin organ cultures.

Gaining insights into the molecular events that govern the progression from melanoma in situ to advanced melanoma and understanding how the local microenvironment at the melanoma site influences this progression are two clinically pivotal aspects that to date are largely unexplored.

In an effort to identify key regulators of the crosstalk between melanoma cells and the melanoma-skin microenvironment, primary and metastatic human melanoma cells were seeded into skin organ cultures (SOCs) and grown for two weeks.

Melanoma cells were recovered from SOCs by laser microdissection and whole-cell tryptic digests were analyzed by nanoflow liquid chromatography-tandem mass spectrometry.

The differential protein abundances were calculated by spectral counting, the results of which provides evidence that cell-matrix and cell-adhesion molecules that are upregulated in the presence of these melanoma cells recapitulate proteomic data obtained from comparative analysis of human biopsies of invasive melanoma and a tissue sample of adjacent, noninvolved skin.

This concordance demonstrates the value of SOCs for conducting proteomic investigations of the melanoma microenvironment.

MedlinePlus Health Information. consumer health - Melanoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Crit Rev Oncol Hematol. 2004 Mar;49(3):245-58 [15036264.001]

[Cites] Clin Exp Metastasis. 2003;20(8):685-700 [14713103.001]

[Cites] Histopathology. 2004 Oct;45(4):405-11 [15469480.001]

[Cites] Methods Mol Biol. 2005;289:61-70 [15502170.001]

[Cites] Z Naturforsch B. 1970 Mar;25(3):332-3 [4392802.001]

[Cites] Am Fam Physician. 1989 May;39(5):203-14 [2655407.001]

[Cites] Crit Rev Biochem Mol Biol. 1989;24(1):41-67 [2667895.001]

[Cites] J Invest Dermatol. 1991 Jul;97(1):20-6 [2056188.001]

[Cites] Cancer Res. 1995 Oct 1;55(19):4283-6 [7671236.001]

[Cites] Nature. 1996 Feb 1;379(6564):466-9 [8559255.001]

[Cites] J Cell Biol. 1996 Nov;135(4):991-1007 [8922382.001]

[Cites] J Pathol. 2006 Oct;210(2):181-91 [16924594.001]

[Cites] Nat Methods. 2007 Mar;4(3):207-14 [17327847.001]

[Cites] J Cell Physiol. 2008 Feb;214(2):504-12 [17708541.001]

[Cites] J Med. 2004;35(1-6):141-9 [18084872.001]

[Cites] Clin Cancer Res. 2008 Feb 15;14(4):1002-14 [18281532.001]

[Cites] Cell Mol Life Sci. 2008 Sep;65(17):2688-701 [18488141.001]

[Cites] J Cancer Res Clin Oncol. 2008 Nov;134(11):1219-27 [18446369.001]

[Cites] Proteomics. 2008 Nov;8(22):4733-47 [18942674.001]

[Cites] Eur J Cancer. 2008 Dec;44(18):2760-5 [19026532.001]

[Cites] Biochim Biophys Acta. 2009 Feb;1794(2):159-67 [18996230.001]

[Cites] PLoS One. 2009;4(4):e5199 [19381273.001]

[Cites] J Proteome Res. 2009 May;8(5):2501-10 [19222175.001]

[Cites] J Cancer Res Clin Oncol. 2009 Sep;135(9):1257-64 [19288131.001]

[Cites] J Biol Chem. 2010 Jan 22;285(4):2591-600 [19920151.001]

[Cites] J Gastrointest Surg. 2009 Nov;13(11):1948-54; discussion 1954 [19760374.001]

[Cites] Cancer Sci. 2010 Feb;101(2):523-9 [19930159.001]

[Cites] Am J Pathol. 2000 Jan;156(1):193-200 [10623667.001]

[Cites] Br J Dermatol. 2000 Feb;142(2):210-22 [10730751.001]

[Cites] Dev Dyn. 2000 Jun;218(2):235-59 [10842355.001]

[Cites] Pigment Cell Res. 2000;13 Suppl 8:68-72 [11041360.001]

[Cites] J Clin Invest. 2001 Apr;107(8):929-34 [11306593.001]

[Cites] Cancer Res. 2001 Jun 1;61(11):4642-3 [11389102.001]

[Cites] J Invest Dermatol. 2001 Nov;117(5):1042-9 [11710911.001]

[Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]

(PMID = 20459140.001).

[ISSN] 1535-3907

[Journal-full-title] Journal of proteome research

[ISO-abbreviation] J. Proteome Res.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA091870-01A2; United States / NCI NIH HHS / CA / R01 CA091870; United States / NCI NIH HHS / CA / R01 CA091870-01A2

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / ACTN4 protein, human; 0 / Tenascin; 11003-00-2 / Actinin

[Other-IDs] NLM/ NIHMS209402; NLM/ PMC3733114

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Environmental exposure to trace elements and risk of cutaneous melanoma.

PURPOSE: Our aim was to examine the risk of melanoma in association with exposure to trace elements of toxicological and nutritional interest.

METHODS: We analyzed the concentrations of cadmium, lead, chromium, selenium, copper and zinc in toenails of 58 patients with newly diagnosed cutaneous melanoma as well as in 58 age- and sex-matched control subjects, randomly selected from the population of Modena province in northern Italy.

RESULTS: Melanoma risk was substantially unrelated to toenail levels of cadmium, chromium, lead and selenium.

A weak direct association between zinc levels and melanoma risk also emerged in the multivariate analysis.

CONCLUSIONS: Overall, these results do not suggest an involvement of heavy metals in melanoma etiology, while they do give some support to a possible role of zinc and, in particular, copper and iron exposure in influencing disease risk.

[MeSH-major] Environmental Exposure. Melanoma / etiology. Melanoma / prevention & control. Metals, Heavy / poisoning. Skin Neoplasms / etiology. Skin Neoplasms / prevention & control

MedlinePlus Health Information. consumer health - Melanoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15785778.001).

[ISSN] 1053-4245

[Journal-full-title] Journal of exposure analysis and environmental epidemiology

[ISO-abbreviation] J Expo Anal Environ Epidemiol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Metals, Heavy; 0 / Trace Elements

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Autocrine amplification loop in statin-induced apoptosis of human melanoma cells.

In particular, melanoma cells have been found to be susceptible to statin-induced apoptosis, although only after longer incubation times.

EXPERIMENTAL APPROACH: The human melanoma A375 and 518A2 cell lines were exposed to various statins in a time-dependent and dose-dependent manner, and indicators of apoptosis, caspase activity and individual apoptotic pathways were analysed for 3-hydroxy-3-methylglutaryl-coenzyme A reductase dependent and independent effects.

CONCLUSIONS AND IMPLICATIONS: Simvastatin and atorvastatin are capable of triggering an 'autocrine' suicide factor, which amplifies apoptosis via the extrinsic pathway in human melanoma cells.

This pro-apoptotic stimulus implies possible therapeutic potential and may guide feasibility for more potent statins in anti-cancer strategies.

[MeSH-minor] Atorvastatin Calcium. Autocrine Communication. Caspase 3 / metabolism. Caspase 8 / metabolism. Caspase 9 / metabolism. Cell Line, Tumor. Enzyme Activation. Heptanoic Acids / pharmacology. Humans. Lovastatin / pharmacology. Melanoma. Pyridines / pharmacology. Pyrroles / pharmacology. Simvastatin / pharmacology. Time Factors

MedlinePlus Health Information. consumer health - Statins.

Hazardous Substances Data Bank. LOVASTATIN .

Hazardous Substances Data Bank. SIMVASTATIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Clin Cancer Res. 1996 Mar;2(3):483-91 [9816194.001]

[Cites] Cancer Res. 1994 Mar 1;54(5):1169-74 [8118801.001]

[Cites] J Atheroscler Thromb. 2004;11(5):253-64 [15557707.001]

[Cites] Melanoma Res. 2005 Apr;15(2):83-9 [15846140.001]

[Cites] Cell. 2005 Jun 3;121(5):671-4 [15935754.001]

[Cites] J Pharmacol Exp Ther. 2005 Sep;314(3):1032-41 [15914674.001]

[Cites] Cancer Immunol Immunother. 2005 Nov;54(11):1127-36 [15889255.001]

[Cites] Nat Rev Cancer. 2005 Dec;5(12):930-42 [16341084.001]

[Cites] JAMA. 2006 Jan 4;295(1):74-80 [16391219.001]

[Cites] Haematologica. 2006 Apr;91(4):542-5 [16585018.001]

[Cites] Dev Cell. 2006 May;10(5):549-61 [16678772.001]

[Cites] Cancer Res. 2006 Sep 1;66(17):8707-14 [16951186.001]

[Cites] Mol Cancer Ther. 2006 Sep;5(9):2310-6 [16985065.001]

[Cites] J Clin Oncol. 2006 Oct 20;24(30):4808-17 [17001070.001]

[Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1538-46 [17077356.001]

[Cites] Mol Cancer Ther. 2007 Jun;6(6):1886-97 [17575117.001]

[Cites] Eur J Cancer. 2007 Nov;43(17):2580-9 [17950596.001]

[Cites] Neoplasia. 2007 Dec;9(12):1078-90 [18084615.001]

[Cites] J Natl Cancer Inst. 2008 Jan 16;100(2):134-9 [18182618.001]

[Cites] BMC Cancer. 2008;8:9 [18199328.001]

[Cites] Melanoma Res. 2008 Apr;18(2):85-94 [18337644.001]

[Cites] Am J Med. 2008 Apr;121(4):302-9 [18374689.001]

[Cites] Curr Opin Pharmacol. 2008 Jun;8(3):333-8 [18243052.001]

[Cites] Clin Cancer Res. 2001 Jan;7(1):158-67 [11205904.001]

[Cites] Int J Cancer. 2002 Jul 1;100(1):111-8 [12115596.001]

[Cites] J Invest Dermatol. 2002 Nov;119(5):1172-6 [12445208.001]

[Cites] Surg Clin North Am. 2003 Feb;83(1):109-56 [12691453.001]

[Cites] Oncogene. 2003 May 19;22(20):3138-51 [12789290.001]

[Cites] Exp Hematol. 2003 Sep;31(9):779-83 [12962723.001]

[Cites] Circulation. 2004 Jun 15;109(23 Suppl 1):III39-43 [15198965.001]

[Cites] Circulation. 2004 Jun 15;109(23 Suppl 1):III50-7 [15198967.001]

[Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]

[Cites] Nature. 1990 Feb 1;343(6257):425-30 [1967820.001]

[Cites] J Clin Pharmacol. 1990 Dec;30(12):1128-35 [2125605.001]

[Cites] Cancer Res. 1991 Jul 1;51(13):3602-9 [1711413.001]

[Cites] Br J Pharmacol. 2004 Nov;143(6):715-24 [15289292.001]

(PMID = 19563533.001).

[ISSN] 1476-5381

[Journal-full-title] British journal of pharmacology

[ISO-abbreviation] Br. J. Pharmacol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biological Factors; 0 / Heptanoic Acids; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Pyridines; 0 / Pyrroles; 48A5M73Z4Q / Atorvastatin Calcium; 9LHU78OQFD / Lovastatin; AGG2FN16EV / Simvastatin; AM91H2KS67 / cerivastatin; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9

[Other-IDs] NLM/ PMC2743847

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Mobile phone use and risk of uveal melanoma: results of the risk factors for uveal melanoma case-control study.

We recently reported an increased risk of uveal melanoma among mobile phone users.

Here, we present the results of a case-control study that assessed the association between mobile phone use and risk of uveal melanoma.

We recruited 459 uveal melanoma case patients at the University of Duisburg-Essen and matched 455 case patients with 827 population control subjects, 133 with 180 ophthalmologist control subjects, and 187 with 187 sibling control subjects.

We used a questionnaire to assess mobile phone use and estimated odds ratios (ORs) and 95% confidence intervals (95% CIs) of risk for uveal melanoma using conditional logistic regression.

Risk of uveal melanoma was not associated with regular mobile phone use (OR = 0.7, 95% CI = 0.5 to 1.0 vs population control subjects; OR = 1.1, 95% CI = 0.6 to 2.3 vs ophthalmologist control subjects; and OR = 1.2, 95% CI = 0.5 to 2.6 vs sibling control subjects), and we observed no trend for cumulative measures of exposure.

We did not corroborate our previous results that showed an increased risk of uveal melanoma among regular mobile phone users.

[MeSH-major] Cell Phones / utilization. Melanoma / epidemiology. Uveal Neoplasms / epidemiology

Genetic Alliance. consumer health - Uveal melanoma.

MedlinePlus Health Information. consumer health - Melanoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ophthalmology. 2007 Jul;114(7):1418; author reply 1418 [17613340.001]

[Cites] Epidemiology. 2001 Jan;12(1):7-12 [11138823.001]

[Cites] Br J Cancer. 2002 Feb 1;86(3):348-9 [11875697.001]

[Cites] Cancer Causes Control. 2003 Apr;14(3):251-7 [12814204.001]

[Cites] Epidemiology. 2003 Jul;14(4):451-8 [12843771.001]

[Cites] Cancer Causes Control. 2004 Feb;15(1):95-6; author reply 101-2 [15049325.001]

[Cites] Eur J Cancer Prev. 2006 Apr;15(2):165-70 [16523014.001]

[Cites] BMC Ophthalmol. 2004;4:11 [15318944.001]

[Cites] Environ Health Perspect. 2004 Dec;112(17):1741-54 [15579422.001]

[Cites] Ann Epidemiol. 2005 May;15(5):321-5 [15840544.001]

[Cites] J Expo Anal Environ Epidemiol. 2005 May;15(3):217-24 [15266354.001]

[Cites] Int J Radiat Biol. 2005 Mar;81(3):189-203 [16019928.001]

[Cites] Am J Epidemiol. 2006 Mar 15;163(6):512-20 [16443797.001]

[Cites] J Expo Anal Environ Epidemiol. 2004 May;14(3):245-8 [15141153.001]

(PMID = 19141780.001).

[ISSN] 1460-2105

[Journal-full-title] Journal of the National Cancer Institute

[ISO-abbreviation] J. Natl. Cancer Inst.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Other-IDs] NLM/ PMC2639317